5 results
1) The BioNIR is non-inferior to the Resolute for the primary clinical endpoint of target lesion failure (TLF) (defined as the composite of cardiac death, target vessel-related MI, or ischemia-driven TLR) at 12 months2/ The BioNIR is non-inferior to…
The BioNIR is non-inferior to the Resolute for the primary angiographic of in-stent late loss at 6 months
To determine the safety, tolerability and pharmacokinetics of an 18-hour i.v. infusion of CLR325 in stable heart failure patients.
Part 1:The purpose of this study is to determine whether LMTM inhibits monoamine oxidase (MAO). MAO is an enzyme (protein involved in reactions in the body) which breaks down tyramine. By giving participants tyramine which raises the blood pressure…
To investigate the effect of microneedling on the patient overall opinion of the abdominal scar quality after a DIEP flap procedure comparing the treated part and the untreated part of the scar after 9 months of follow up.